SageView Advisory Group’s Vaxcyte PCVX Stock Holding History

SageView Advisory Group’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-114	Closed	-$5.26K	–	1886
2025 Q4	$5.26K	Buy	+114	New	+$5.1K	﹤0.01%	1956

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SageView Advisory Group's PCVX Position: Q1 2026 in Review

SageView Advisory Group sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 114 shares — an estimated $5.26K sold.

SageView Advisory Group first reported a position in PCVX in Q4 2025 and held it in 1 quarter. The position peaked at $5.26K in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

SageView Advisory Group reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 114 Vaxcyte shares in Q1 2026, an estimated $5.26K.
SageView Advisory Group first reported a position in Vaxcyte in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Vaxcyte position peaked at $5.26K in Q4 2025.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.